Shaping the Future of Community Bispecific Administration: Lessons From ASH 2025

EP: 1.Single Bispecific Strategy Shows Operational Efficiencies, Cost Savings in DLBCL and FL

EP: 2.Streamlining Lymphoma Care With Multi-Indication Bispecifics

EP: 3.Overcoming Operational Barriers to Bispecific Use in Community Oncology

EP: 4.Building Confidence in Community Bispecific Use Through Standardization

EP: 5.The Promise and Limits of Remote Patient Monitoring for Bispecific Antibodies

EP: 6.RPM Shows Promise for Safer, More Feasible Outpatient Bispecific Administration

EP: 7.Optimizing Adverse Event Management for Bispecific Antibodies in the Community

Now Viewing

EP: 8.Shaping the Future of Community Bispecific Administration: Lessons From ASH 2025

Tara M. Graff, DO, director of clinical research at Mission Cancer + Blood at the University of Iowa Health Care, reflected on data from ASH 2025 highlighting operational, educational, and monitoring strategies that are collectively shaping the future of bispecific antibody delivery in routine oncology practice, particularly in the community setting. Drawing on years of experience onboarding community oncology groups nationwide, Graff emphasized that meaningful progress is already underway.

She noted that many practices initially lacked even basic operating procedures for bispecific administration but are now developing standardized workflows, educational frameworks, and monitoring strategies tailored to their resources. Through peer-to-peer learning, collaboration with academic centers, and support from industry, community practices are increasingly building the infrastructure needed to safely deliver these therapies. Importantly, Graff highlighted that progress has accelerated dramatically over the past 3 years—and even in recent months—as familiarity grows and best practices are more widely shared.

Across the abstracts, common themes emerged: the value of standardized protocols for adverse event management, the role of education in improving clinician confidence, the promise of remote patient monitoring to support outpatient care, and the importance of demonstrating cost-effectiveness to support payer acceptance. Together, these strategies help reduce variability, improve safety, and make outpatient bispecific delivery more feasible for practices of varying sizes.

Graff underscored that slow adoption is not unique to bispecifics, pointing to similar trajectories seen with anti-CD20 antibodies and immune checkpoint inhibitors. Comfort with new therapies develops over time and requires alignment across clinical, operational, and financial domains. She stressed that community practices already possess the clinical expertise needed; the remaining challenge lies in building trust, refining infrastructure, and learning through shared experience.

Looking ahead, Graff expressed optimism that continued collaboration and education will further expand access to bispecific antibodies. As practices learn from one another and refine their approaches, she expects community-based delivery to become increasingly routine—bringing advanced therapies closer to patients’ homes.